Corpus
PascalFrancis
Racine
Corpus
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

A Pilot Study Using Nabilone for Symptomatic Treatment in Huntington's Disease

Identifieur interne : 000D09 ( PascalFrancis/Corpus ); précédent : 000D08; suivant : 000D10

A Pilot Study Using Nabilone for Symptomatic Treatment in Huntington's Disease

Auteurs : Adrienne Curtis ; Ian Mitchell ; Smitaa Patel ; Natalie Ives ; Hugh Rickards

Source :

RBID : Pascal:10-0036269

Descripteurs français

English descriptors

Abstract

Pilot study of nabilone in Huntington's disease (HD). Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. Primary outcome, Unified Hunting-ton's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: -1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: -3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: -0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  1    @0 0885-3185
A03   1    @0 Mov. disord.
A05       @2 24
A06       @2 15
A08 01  1  ENG  @1 A Pilot Study Using Nabilone for Symptomatic Treatment in Huntington's Disease
A11 01  1    @1 CURTIS (Adrienne)
A11 02  1    @1 MITCHELL (Ian)
A11 03  1    @1 PATEL (Smitaa)
A11 04  1    @1 IVES (Natalie)
A11 05  1    @1 RICKARDS (Hugh)
A14 01      @1 Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust @2 Edgbaston, Birmingham @3 GBR @Z 1 aut. @Z 5 aut.
A14 02      @1 University of Birmingham School of Psychology @2 Edgbaston, Birmingham @3 GBR @Z 2 aut.
A14 03      @1 University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute @2 Edgbaston, Birmingham @3 GBR @Z 3 aut. @Z 4 aut.
A20       @1 2254-2259
A21       @1 2009
A23 01      @0 ENG
A43 01      @1 INIST @2 20953 @5 354000171746820110
A44       @0 0000 @1 © 2010 INIST-CNRS. All rights reserved.
A45       @0 14 ref.
A47 01  1    @0 10-0036269
A60       @1 P
A61       @0 A
A64 01  1    @0 Movement disorders
A66 01      @0 USA
C01 01    ENG  @0 Pilot study of nabilone in Huntington's disease (HD). Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. Primary outcome, Unified Hunting-ton's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: -1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: -3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: -0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted.
C02 01  X    @0 002B17
C02 02  X    @0 002B17G
C03 01  X  FRE  @0 Chorée de Huntington @5 01
C03 01  X  ENG  @0 Huntington disease @5 01
C03 01  X  SPA  @0 Corea Huntington @5 01
C03 02  X  FRE  @0 Syndrome choréique @5 02
C03 02  X  ENG  @0 Chorea @5 02
C03 02  X  SPA  @0 Corea síndrome @5 02
C03 03  X  FRE  @0 Trouble psychiatrique @5 03
C03 03  X  ENG  @0 Mental disorder @5 03
C03 03  X  SPA  @0 Trastorno psiquiátrico @5 03
C03 04  X  FRE  @0 Pathologie du système nerveux @5 04
C03 04  X  ENG  @0 Nervous system diseases @5 04
C03 04  X  SPA  @0 Sistema nervioso patología @5 04
C03 05  X  FRE  @0 Nabilone @2 NK @2 FR @5 09
C03 05  X  ENG  @0 Nabilone @2 NK @2 FR @5 09
C03 05  X  SPA  @0 Nabilona @2 NK @2 FR @5 09
C03 06  X  FRE  @0 Traitement @5 10
C03 06  X  ENG  @0 Treatment @5 10
C03 06  X  SPA  @0 Tratamiento @5 10
C03 07  X  FRE  @0 Cannabinoïde @5 11
C03 07  X  ENG  @0 Cannabinoid @5 11
C03 07  X  SPA  @0 Canabinoide @5 11
C07 01  X  FRE  @0 Pathologie de l'encéphale @5 37
C07 01  X  ENG  @0 Cerebral disorder @5 37
C07 01  X  SPA  @0 Encéfalo patología @5 37
C07 02  X  FRE  @0 Syndrome extrapyramidal @5 38
C07 02  X  ENG  @0 Extrapyramidal syndrome @5 38
C07 02  X  SPA  @0 Extrapiramidal síndrome @5 38
C07 03  X  FRE  @0 Maladie dégénérative @5 39
C07 03  X  ENG  @0 Degenerative disease @5 39
C07 03  X  SPA  @0 Enfermedad degenerativa @5 39
C07 04  X  FRE  @0 Maladie héréditaire @5 40
C07 04  X  ENG  @0 Genetic disease @5 40
C07 04  X  SPA  @0 Enfermedad hereditaria @5 40
C07 05  X  FRE  @0 Pathologie du système nerveux central @5 41
C07 05  X  ENG  @0 Central nervous system disease @5 41
C07 05  X  SPA  @0 Sistema nervosio central patología @5 41
C07 06  X  FRE  @0 Mouvement involontaire @5 43
C07 06  X  ENG  @0 Involuntary movement @5 43
C07 06  X  SPA  @0 Movimiento involuntario @5 43
C07 07  X  FRE  @0 Trouble neurologique @5 44
C07 07  X  ENG  @0 Neurological disorder @5 44
C07 07  X  SPA  @0 Trastorno neurológico @5 44
N21       @1 025
N44 01      @1 OTO
N82       @1 OTO

Format Inist (serveur)

NO : PASCAL 10-0036269 INIST
ET : A Pilot Study Using Nabilone for Symptomatic Treatment in Huntington's Disease
AU : CURTIS (Adrienne); MITCHELL (Ian); PATEL (Smitaa); IVES (Natalie); RICKARDS (Hugh)
AF : Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust/Edgbaston, Birmingham/Royaume-Uni (1 aut., 5 aut.); University of Birmingham School of Psychology/Edgbaston, Birmingham/Royaume-Uni (2 aut.); University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute/Edgbaston, Birmingham/Royaume-Uni (3 aut., 4 aut.)
DT : Publication en série; Niveau analytique
SO : Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 15; Pp. 2254-2259; Bibl. 14 ref.
LA : Anglais
EA : Pilot study of nabilone in Huntington's disease (HD). Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. Primary outcome, Unified Hunting-ton's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: -1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: -3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: -0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted.
CC : 002B17; 002B17G
FD : Chorée de Huntington; Syndrome choréique; Trouble psychiatrique; Pathologie du système nerveux; Nabilone; Traitement; Cannabinoïde
FG : Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Maladie héréditaire; Pathologie du système nerveux central; Mouvement involontaire; Trouble neurologique
ED : Huntington disease; Chorea; Mental disorder; Nervous system diseases; Nabilone; Treatment; Cannabinoid
EG : Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Genetic disease; Central nervous system disease; Involuntary movement; Neurological disorder
SD : Corea Huntington; Corea síndrome; Trastorno psiquiátrico; Sistema nervioso patología; Nabilona; Tratamiento; Canabinoide
LO : INIST-20953.354000171746820110
ID : 10-0036269

Links to Exploration step

Pascal:10-0036269

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">A Pilot Study Using Nabilone for Symptomatic Treatment in Huntington's Disease</title>
<author>
<name sortKey="Curtis, Adrienne" sort="Curtis, Adrienne" uniqKey="Curtis A" first="Adrienne" last="Curtis">Adrienne Curtis</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Mitchell, Ian" sort="Mitchell, Ian" uniqKey="Mitchell I" first="Ian" last="Mitchell">Ian Mitchell</name>
<affiliation>
<inist:fA14 i1="02">
<s1>University of Birmingham School of Psychology</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name>
<affiliation>
<inist:fA14 i1="03">
<s1>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
<affiliation>
<inist:fA14 i1="03">
<s1>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Rickards, Hugh" sort="Rickards, Hugh" uniqKey="Rickards H" first="Hugh" last="Rickards">Hugh Rickards</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">10-0036269</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 10-0036269 INIST</idno>
<idno type="RBID">Pascal:10-0036269</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D09</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">A Pilot Study Using Nabilone for Symptomatic Treatment in Huntington's Disease</title>
<author>
<name sortKey="Curtis, Adrienne" sort="Curtis, Adrienne" uniqKey="Curtis A" first="Adrienne" last="Curtis">Adrienne Curtis</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Mitchell, Ian" sort="Mitchell, Ian" uniqKey="Mitchell I" first="Ian" last="Mitchell">Ian Mitchell</name>
<affiliation>
<inist:fA14 i1="02">
<s1>University of Birmingham School of Psychology</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name>
<affiliation>
<inist:fA14 i1="03">
<s1>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
<affiliation>
<inist:fA14 i1="03">
<s1>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Rickards, Hugh" sort="Rickards, Hugh" uniqKey="Rickards H" first="Hugh" last="Rickards">Hugh Rickards</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Cannabinoid</term>
<term>Chorea</term>
<term>Huntington disease</term>
<term>Mental disorder</term>
<term>Nabilone</term>
<term>Nervous system diseases</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Chorée de Huntington</term>
<term>Syndrome choréique</term>
<term>Trouble psychiatrique</term>
<term>Pathologie du système nerveux</term>
<term>Nabilone</term>
<term>Traitement</term>
<term>Cannabinoïde</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Pilot study of nabilone in Huntington's disease (HD). Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. Primary outcome, Unified Hunting-ton's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: -1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: -3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: -0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0885-3185</s0>
</fA01>
<fA03 i2="1">
<s0>Mov. disord.</s0>
</fA03>
<fA05>
<s2>24</s2>
</fA05>
<fA06>
<s2>15</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>A Pilot Study Using Nabilone for Symptomatic Treatment in Huntington's Disease</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>CURTIS (Adrienne)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>MITCHELL (Ian)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>PATEL (Smitaa)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>IVES (Natalie)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>RICKARDS (Hugh)</s1>
</fA11>
<fA14 i1="01">
<s1>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>University of Birmingham School of Psychology</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20>
<s1>2254-2259</s1>
</fA20>
<fA21>
<s1>2009</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>20953</s2>
<s5>354000171746820110</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>14 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>10-0036269</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Movement disorders</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Pilot study of nabilone in Huntington's disease (HD). Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. Primary outcome, Unified Hunting-ton's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: -1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: -3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: -0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Chorée de Huntington</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Huntington disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Corea Huntington</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Syndrome choréique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Chorea</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Corea síndrome</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Trouble psychiatrique</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Mental disorder</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Trastorno psiquiátrico</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Pathologie du système nerveux</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Nabilone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Nabilone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Nabilona</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Traitement</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Treatment</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Tratamiento</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Cannabinoïde</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Cannabinoid</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Canabinoide</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Maladie héréditaire</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Genetic disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Enfermedad hereditaria</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Pathologie du système nerveux central</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Mouvement involontaire</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Involuntary movement</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Movimiento involuntario</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Trouble neurologique</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Neurological disorder</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Trastorno neurológico</s0>
<s5>44</s5>
</fC07>
<fN21>
<s1>025</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
<server>
<NO>PASCAL 10-0036269 INIST</NO>
<ET>A Pilot Study Using Nabilone for Symptomatic Treatment in Huntington's Disease</ET>
<AU>CURTIS (Adrienne); MITCHELL (Ian); PATEL (Smitaa); IVES (Natalie); RICKARDS (Hugh)</AU>
<AF>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust/Edgbaston, Birmingham/Royaume-Uni (1 aut., 5 aut.); University of Birmingham School of Psychology/Edgbaston, Birmingham/Royaume-Uni (2 aut.); University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute/Edgbaston, Birmingham/Royaume-Uni (3 aut., 4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 15; Pp. 2254-2259; Bibl. 14 ref.</SO>
<LA>Anglais</LA>
<EA>Pilot study of nabilone in Huntington's disease (HD). Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. Primary outcome, Unified Hunting-ton's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: -1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: -3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: -0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted.</EA>
<CC>002B17; 002B17G</CC>
<FD>Chorée de Huntington; Syndrome choréique; Trouble psychiatrique; Pathologie du système nerveux; Nabilone; Traitement; Cannabinoïde</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Maladie héréditaire; Pathologie du système nerveux central; Mouvement involontaire; Trouble neurologique</FG>
<ED>Huntington disease; Chorea; Mental disorder; Nervous system diseases; Nabilone; Treatment; Cannabinoid</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Genetic disease; Central nervous system disease; Involuntary movement; Neurological disorder</EG>
<SD>Corea Huntington; Corea síndrome; Trastorno psiquiátrico; Sistema nervioso patología; Nabilona; Tratamiento; Canabinoide</SD>
<LO>INIST-20953.354000171746820110</LO>
<ID>10-0036269</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D09 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000D09 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0036269
   |texte=   A Pilot Study Using Nabilone for Symptomatic Treatment in Huntington's Disease
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024